MMP3 and rheumatoid arthritis: Infliximab-treatment blunted MMP-3 (RA: 1.30 ± 0.25, n = 7 vs. RA Infliximab: 0.53 ± 0.09, n = 7; P = 0.0116, Fig. 4A,B) and MMP-9 (RA: 1.36 ± 0.35, n = 7 vs. RA Infliximab: 0.45 ± 0.11, n = 7; P = 0.0254, Fig. 4C,D) levels.